|
|
The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia
|
|
|
Acadia Pharmaceuticals and StoryCorps Collaborate to Launch Yours, Truly – a Multicultural Storytelling Campaign to Bring Greater Awareness to Parkinson’s Disease Non-Motor Symptoms
|
|
|
Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results
|
|
|
Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021
|
|
|
Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial
|
|
|
Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021
|
|
|
Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson’s Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
|
|
|
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
|
Acadia Pharmaceuticals Announces Executive Leadership Change
|
|
|
Acadia Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021
|
|
|
Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results
|
|
|
The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis
|
|
|
Acadia Pharmaceuticals to Announce Second Quarter 2021 Financial Results on August 4, 2021
|
|
|
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the Alzheimer’s Association International Conference 2021 (AAIC)
|
|
|
NUPLAZID® (pimavanserin) Efficacy Data from Open-Label Extension (OLE) Study Published in Parkinsonism and Related Disorders
|
|
|
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
|
Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results
|
|
|
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
|
Acadia Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021
|
|
|
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
|
|
|
Acadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
|
|
|
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
|
|
|
Acadia Pharmaceuticals Recognizes National Caregiver’s Day with Launch of MoreThanMemoryLoss.com
|
|
|
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
|
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
|
|
|
Acadia Pharmaceuticals Announces Commercial Leadership Change
|
